Other signaling pathways emerging as potential chemotherapeutic targets for breast cancer (Núñez-Marrero, 2019; Wood et al., 2018), including the IL-12/STAT4 pathway and the JNK1/2 pathway, were also altered by triterpenes, showcasing their versatile abilities to suppress breast cancer. Here, STAT4 is linked to breast carcinoma.